Osteoprotegerin as a Marker of Atherosclerosis in Diabetic Patients

Augoulea, Areti; Vrachnis, Nikolaos; Lambrinoudaki, Ιrene; Dafopoulos, Konstantinos; Iliodromiti, Zoe; Daniilidis, Angelos; Varras, M; Alexandrou, Andreas; Deligeoroglou, Efthymios; Creatsas, George

doi:10.1155/2013/182060

Cited by 33 publications

(23 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main findings of this study reveal significantly higher plasma OPG levels in children with T1D compared to controls. Our result is in agreement with previous studies . However, Singh et al showed opposite results by finding significant lower serum OPG levels in patients with T1D compared to controls (Table ).…”

Section: Discussionsupporting

confidence: 93%

“…A significant increase of OPG levels has been related to the glucose level ≥ 7 mmol/L (2.44 [0.01-6.22] vs. 2. 16 [0. 13-6.22] pmol/L, p = 0.019), microalbuminuria ≥ 30 mg/24 h (3.71 [0.160-6.03] vs. 2.26 [0.01-6.22] pmol/L, p < 0.001), and cystatin-C ≥ 0.789 mg/L (2.64 [0.37-6.22] vs. 2.11 [0.01-5.82] pmol/L, p < 0.001).…”

Section: Original Articlementioning

confidence: 99%

“…A total of 243 subjects were recruited to participate in this study; 143 children and adolescents with T1D from the pediatric department (median age 12 [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] yr, 92 males and 51 females), and 100 healthy children and adolescent without any evidence of diabetes, as control group (median age 12 [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18] yr, 62 males and 38 females). Patients have a median duration of diabetes 4 [1][2][3][4][5][6] yr.…”

Section: Study Populationmentioning

confidence: 99%

See 2 more Smart Citations

Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes

Fekih

Triki

et al. 2016

Pediatr Diabetes

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Original Articlementioning

confidence: 99%

Section: Study Populationmentioning

confidence: 99%

See 1 more Smart Citation

Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes

Fekih

Triki

et al. 2016

Pediatr Diabetes

View full text Add to dashboard Cite

show abstract

“…In a review that evaluated studies examining OPG levels with indices of atherosclerosis, cardiovascular events, and glycemic control in diabetic patients, the existing data were found to be as yet sparse (30). In our study, we could only find a correlation between type 1 DM and OPG levels, but not for type 2 DM, which shows the lack of evidence for suggesting OPG as a certain biomarker of atherosclerosis for all kinds and stages of diabetes.…”

Section: Discussioncontrasting

confidence: 86%

Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients

Alkac¹,

Alkaç²,

Akbaş³

et al. 2015

Turk J Med Sci

View full text Add to dashboard Cite

IntroductionDiabetes mellitus (DM), the most common endocrine disorder globally, is increasingly prevalent. It causes serious medical and socioeconomic problems due to its microvascular and macrovascular complications. It is common knowledge that diabetes is an independent risk factor for atherosclerotic heart disease (1). Thus, early detection of atherosclerotic complications in diabetes is vital to decreasing morbidity and mortality.Osteoprotegerin (OPG) is a glycoprotein and a member of the tumor necrosis factor receptor family initially found in the bone. Its main function is to inhibit both the differentiation and action of osteoclasts by binding and neutralizing the receptor activator for NF-kB ligand (RANKL), which is known to have osteoclast-inducing activity (2). Recent studies showed that increased OPG levels were an independent risk factor for atherosclerosis and cardiovascular diseases, and suggested that this cytokine could be used as a marker of coronary artery disease (3).Ankle-brachial index (ABI) is the ratio of ankle systolic blood pressure to arm systolic blood pressure. ABI measurement is a noninvasive indicator of peripheral artery disease and atherosclerosis and is independent of symptom presence. Various studies have shown that low ABI (≤0.9) is related to increased mortality, coronary heart disease, congestive heart failure, stroke, and dementia (4-13).In our study, we investigated the availability of OPG as a marker of atherosclerosis by comparing serum OPG levels with ABI in type 1 and type 2 diabetic patients with no macrovascular complications. Materials and methodsThis was a cross-sectional study. We recruited 31 type 1 DM and 31 type 2 DM patients without any macrovascular complications from our diabetes outpatient clinic, and 20 healthy consecutive patients, who did not have any chronical diseases and were not on any medications for Background/aim: The aim of this study was to investigate the availability of osteoprotegerin (OPG) as a marker of atherosclerosis and compare serum OPG levels with ankle-brachial index (ABI) in diabetic patients. Materials and methods:A total of 31 type 1 and 31 type 2 diabetic patients without macrovascular complications and 20 healthy volunteers were included. Serum OPG levels and ABI were measured. Results:The duration of diabetes was significantly higher in type 1 diabetics than in type 2, although there was no significant difference between mean HbA1c levels. There was a weak and inverse correlation between OPG and atherosclerosis in type 1 diabetics only (P = 0.046, r = -0.360). There was a weak, positive correlation between ABI and HbA1c in all participant groups (P = 0.047, r = 0.220), and a weak-medium correlation in type 2 diabetics (P = 0.021, r = 0.414). After the adjustment of OPG levels to atherosclerosis risk factors, only the age factor was found to be effective on OPG. Conclusion:The inverse correlation of serum OPG with atherosclerosis in type 1 diabetics suggests that atherosclerosis may be related to increased duration of diabetes. Si...

show abstract

“…Different studies have shown that OPG levels are elevated in patients with type 1 diabetes mellitus ( Table 2 ). Furthermore, prepubertal children with type 1 diabetes have significantly increased OPG levels [ 28 ]. Besides, Xiang et al [ 29 ] also observed increased OPG in these patients.…”

Section: Osteoprotegerin In Clinical Studiesmentioning

confidence: 99%

Osteoprotegerin in Cardiometabolic Disorders

Ciriza

Lawrie

Varo

2015

International Journal of Endocrinology

View full text Add to dashboard Cite

Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD, and as such OPG has emerged as a potential biomarker for CVD. This review focuses on the relationship between circulating OPG and different endocrine cardiometabolic alterations such as type 1 and 2 diabetes. The association of OPG with diabetic complications (neuropathy, nephropathy, or retinopathy) as well as with atherosclerosis, coronary artery calcification, morbidity, and mortality is pointed out. Moreover, OPG modulation by different treatments is also established. Besides, other associated diseases such as obesity, hypertension, and metabolic syndrome, which are known cardiovascular risk factors, are also considered.

show abstract

Osteoprotegerin as a Marker of Atherosclerosis in Diabetic Patients

Cited by 33 publications

References 70 publications

Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes

Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes

Osteoprotegerin as a marker of atherosclerosis in type 1 and type 2 diabetic patients

Osteoprotegerin in Cardiometabolic Disorders

Contact Info

Product

Resources

About